- Home
- CABA vs GDYN Comparison
CABA vs GDYN Comparison
Compare CABA & GDYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CABA | GDYN |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 495.7M | 509.3M |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CABA | GDYN |
|---|---|---|
| Price | $3.25 | $7.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $14.50 | $10.67 |
| AVG Volume (30 Days) | ★ 4.2M | 1.5M |
| Earning Date | 05-14-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 10.26 | ★ 120.00 |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | ★ $111,283,000.00 |
| Revenue This Year | N/A | $10.16 |
| Revenue Next Year | N/A | $10.84 |
| P/E Ratio | ★ N/A | $399.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.44 | $5.11 |
| 52 Week High | $4.23 | $10.21 |
Technical Indicators
Market Signals| Indicator | CABA | GDYN |
|---|---|---|
| Relative Strength Index (RSI) | 58.51 | 61.42 |
| Support Level | $3.12 | $6.00 |
| Resistance Level | $3.34 | $8.13 |
| Average True Range (ATR) | 0.22 | 0.28 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 68.32 | 51.66 |
Price Performance
Historical ComparisonAbout CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
About GDYN Grid Dynamics Holdings Inc.
Grid Dynamics Holdings Inc is a provider of technology consulting, platform and product engineering, and advanced analytics services. The company delivers tailored solutions in several industry verticals like Tech, Media and Telecom, Retail, Finance and Consumer Packaged goods (CPG)/manufacturing. The company derives maximum revenue from Retails. Geographically company earns revenue from North America, Europe and other regions.